Loading...
01/11 11:07
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals. The company shows revenue growth and improved gross margins in teleradiology services, but faces challenges with AI solutions and a slight net loss increase. The Q&A section reveals unclear management responses, especially regarding system deployment, raising concerns. Despite optimistic guidance for future breakeven and revenue targets, the absence of immediate catalysts and some operational uncertainties suggest a neutral stock price movement over the next two weeks.
GAAP Net Loss $13.7 million for Q3 2025, compared to $13.6 million in Q3 2024. The slight increase in net loss is attributed to higher non-GAAP operating expenses.
Revenue $3.4 million for Q3 2025, compared to $3.0 million in Q3 2024, representing a $0.4 million increase. This increase stems from a $0.6 million rise in revenue from teleradiology services, offset by a $0.3 million decrease in AI solutions revenue and a $0.1 million increase in imaging systems and OEM services revenue.
Gross Loss (GAAP) $2.9 million for Q3 2025, compared to $2.8 million in Q3 2024. The increase is due to higher costs associated with revenue generation.
Teleradiology Services Revenue $3.1 million for Q3 2025, compared to $2.6 million in Q3 2024, representing a $0.5 million increase. The growth is attributed to customer retention, increased rates, and higher service volumes during weekends and weekdays.
Teleradiology Services Gross Profit Margin (GAAP) 25% for Q3 2025, compared to 13% in Q3 2024. The improvement is due to increased rates and higher service volumes.
AI Solutions Revenue $0.1 million for Q3 2025, compared to $0.4 million in Q3 2024, representing a $0.3 million decrease. The decline is attributed to reduced demand or sales in this segment.
AI Solutions Gross Loss (GAAP) $1.9 million for Q3 2025, compared to $1.6 million in Q3 2024. The increase in gross loss is due to lower revenue and higher associated costs.
Research and Development Expenses $4.6 million for Q3 2025, compared to $4.7 million in Q3 2024, representing a $0.1 million decrease. The reduction is due to lower share-based compensation and development activity expenses, partially offset by higher salaries and wages.
Sales and Marketing Expenses $1.5 million for Q3 2025, compared to $0.9 million in Q3 2024, representing a $0.6 million increase. The rise is due to higher salaries, wages, and marketing activities related to U.S. market commercialization.
General and Administrative Expenses $5.3 million for Q3 2025, compared to $5.7 million in Q3 2024, representing a $0.4 million decrease. The reduction is due to lower share-based compensation, legal expenses, and D&O insurance costs, partially offset by higher salaries and recruiting fees.
Nanox.ARC X system: A next-generation platform to be unveiled at the RSNA Annual Meeting. It features a smaller footprint, simplified installation process, and flexibility to support additional clinical indications. It is AI-ready and designed to expand the addressable market significantly.
TAP2D software module: Submitted to the FDA for approval. It is a 2D view image output for the Nanox.ARC systems, aimed at enhancing diagnostic confidence for radiologists.
European market expansion: Signed distribution agreements in the Czech Republic and France, following agreements in Greece and Romania. These partnerships aim to strengthen Nanox's presence across Europe.
U.S. market expansion: Acquired VasoHealthcare IT to enhance AI integration and customer service. Collaborated with 3DR Labs to distribute AI solutions to over 1,800 hospitals and imaging centers in the U.S.
India market entry: Signed a distribution agreement with an Indian partner and initiated two pilot projects.
Manufacturing partnerships: Collaborated with Fabrinet for scalable manufacturing of Nanox.ARC systems and with Varex for tube production. Enhanced tube manufacturing infrastructure to support future demand.
Operational efficiency: Focused on creating a leaner organization and improving production capabilities to support long-term success.
AI integration: Acquired VasoHealthcare IT to connect FDA-cleared imaging AI solutions with IT expertise, aiming to transform Nanox into a comprehensive imaging platform.
Clinical collaborations: Partnered with Cedars-Sinai and other institutions for clinical trials to validate the use of Nanox.ARC in lung cancer detection and other applications.
Regulatory Challenges: The company is facing delays in regulatory approvals in various countries outside the U.S., which is slowing down their global deployment efforts. Additionally, the adjunctive use limitation in the U.S. market is restricting the full commercialization of their Nanox.ARC system.
Supply Chain and Manufacturing Risks: The company is dependent on third-party manufacturers and suppliers for critical components, including digital X-ray tubes and chips. Any disruptions or delays in the supply chain could impact production and deployment timelines.
Financial Losses: The company reported a GAAP net loss of $13.7 million for Q3 2025, with ongoing losses in their AI solutions and imaging systems segments. This financial strain could impact their ability to execute strategic initiatives.
Market Penetration Challenges: Despite progress, the company is still in the early stages of market penetration, with only a limited number of systems deployed and operational. This could delay revenue generation and market adoption.
Economic and Competitive Pressures: The company faces competitive pressures in the medical imaging and AI sectors, which could impact their market share and pricing strategies. Additionally, economic uncertainties could affect customer budgets and purchasing decisions.
Operational Efficiency Risks: Efforts to streamline operations and achieve sustainable growth may face challenges, including the need to scale manufacturing and maintain cost efficiency while expanding globally.
Revenue Guidance for 2026: The company is guiding for more than $35 million in revenues for 2026.
EBITDA Breakeven Projections: The AI business segment, with the addition of VHC IT, is expected to achieve EBITDA breakeven on a quarterly basis sometime in 2026. Nanox as a whole is projected to reach EBITDA breakeven on a quarterly basis in 2027.
Nanox.ARC Deployment Goals: The company aims to deploy 100 systems worldwide for clinical demo and commercial purposes by the end of 2025. Additionally, the next-generation Nanox.ARC X system will be launched at the RSNA Annual Meeting, designed to expand market penetration with a smaller footprint and simplified installation process.
Regulatory Advancements: The company is working with the FDA to remove the adjunctive use limitation for the Nanox.ARC, which would allow it to be marketed as a stand-alone modality. This is expected to unlock significant new market opportunities.
AI Integration and Expansion: Nanox is acquiring VasoHealthcare IT to enhance its AI capabilities and integration. The acquisition is expected to accelerate the deployment of Nanox.AI solutions across U.S. healthcare facilities and generate scalable recurring revenues.
Global Market Expansion: The company is expanding its presence in Europe with new distribution agreements in the Czech Republic and France. It is also working on regulatory approvals in various countries to scale globally.
Clinical Trials and Collaborations: Nanox is conducting clinical trials and collaborations, including partnerships with Cedars-Sinai and MDS Wellness, to validate the use of its technology in lung cancer detection and other applications.
Manufacturing and Supply Chain: The company is scaling its manufacturing capabilities through partnerships with Fabrinet and other suppliers to meet anticipated future demand for its systems.
The selected topic was not discussed during the call.
The earnings call presents mixed signals. The company shows revenue growth and improved gross margins in teleradiology services, but faces challenges with AI solutions and a slight net loss increase. The Q&A section reveals unclear management responses, especially regarding system deployment, raising concerns. Despite optimistic guidance for future breakeven and revenue targets, the absence of immediate catalysts and some operational uncertainties suggest a neutral stock price movement over the next two weeks.
The earnings call presents a mixed picture: slight revenue growth and strategic market expansion are positive, but increased losses and vague management responses in the Q&A section are concerning. The company's focus on AI and regulatory achievements offer long-term potential, but short-term financial metrics and execution risks temper optimism. With no clear guidance improvement, the stock is likely to remain stable in the near term.
The earnings call reveals financial struggles, with increased losses and minimal revenue from imaging systems. Despite some growth in AI solutions and teleradiology, profitability remains elusive. The lack of a shareholder return plan and unclear breakeven timeline further dampen sentiment. While there are positive developments like market expansion and regulatory achievements, the overall financial health and guidance provided are weak, leading to a likely negative stock price reaction.
The earnings call highlights several negative aspects: increased financial losses, minimal revenue generation, and lack of a shareholder return plan. While there are some positive indicators, such as regulatory achievements and market expansion plans, these are overshadowed by financial struggles and unclear guidance. The Q&A session reveals concerns about deployment delays and lack of clear break-even strategy. Despite some growth in teleradiology, the overall sentiment is negative due to increased losses and uncertainties, likely leading to a negative stock price reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
